Skip to main content
Oncolys BioPharma Inc. logo

Oncolys BioPharma Inc. — Investor Relations & Filings

Ticker · 4588 ISIN · JP3202170001 T Manufacturing
Open in API
Filings indexed 83 across all filing types
Latest filing 2017-05-08 Interim / Quarterly Rep…
Country JP Japan
Listing T 4588

About Oncolys BioPharma Inc.

https://www.oncolys.com/en/

Oncolys BioPharma Inc. is a biopharmaceutical company focused on the research and development of breakthrough therapies and diagnostics for cancer. The company's core technology is oncolytic virotherapy, which utilizes viruses to selectively target and destroy cancer cells. Its development pipeline addresses multiple stages of cancer care, spanning from early detection and prognostic testing to loco-regional and systemic treatments. The company aims to develop innovative and effective drugs to meet the needs of patients and healthcare providers in the field of oncology.

Recent filings

Filing Released Lang Actions
四半期報告書－第14期第1四半期(2017/01/01－2017/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act in Japan. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the fiscal year 2017 (January 1, 2017, to March 31, 2017). It includes management analysis, business risks, and share information. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. Q1 2017
2017-05-08 Japanese
有価証券報告書－第13期(2016/01/01－2016/12/31)
Annual Report Classification · 100% confidence The document is a 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains comprehensive financial statements, business descriptions, and management information for the fiscal year ending December 31, 2016. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2016
2017-03-31 Japanese
四半期報告書－第13期第3四半期(2016/07/01－2016/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Oncolys BioPharma Inc., covering the third quarter of the fiscal year 2016 (ending September 30, 2016). It contains detailed financial statements (balance sheet, income statement), segment information, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2016
2016-11-04 Japanese
四半期報告書－第13期第2四半期(2016/04/01－2016/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Oncolys BioPharma Inc., covering the period from April 1, 2016, to June 30, 2016. It contains detailed financial statements, management analysis of financial results, and operational updates, which are characteristic of an interim/quarterly report. It is not an announcement of a report, but the report itself, containing substantive financial data. H1 2016
2016-08-04 Japanese
四半期報告書－第13期第1四半期(2016/01/01－2016/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Oncolys BioPharma Inc., covering the period from January 1, 2016, to March 31, 2016. It contains detailed financial statements, including the balance sheet, income statement, and segment information, as required by the Financial Instruments and Exchange Act of Japan. Since it is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial data, it is classified as an Interim/Quarterly Report (IR). Q1 2016
2016-05-10 Japanese
訂正有価証券報告書－第12期(2015/01/01－2015/12/31)
Annual Report Classification · 100% confidence The document is a '訂正有価証券報告書' (Amended Securities Report) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial tables, business history, and management information for Oncolys BioPharma Inc. for the fiscal year ending December 31, 2015. As it is a comprehensive annual financial report (10-K equivalent in the Japanese regulatory context), it is classified as a 10-K. FY 2015
2016-03-30 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.